Develops small molecules drug candidates in infectious & metabolic diseases and oncology

ENYO Pharma is focused on developing innovative therapeutics aimed at improving the quality of life for patients suffering from impaired kidney function. Their lead compound, Vonafexor, is a synthetic small molecule that acts as a highly selective farnesoid X receptor (FXR) agonist. This unique compound is designed to activate FXR without affecting other nuclear receptors, which allows it to induce a specific set of target genes. Vonafexor is currently undergoing Phase 2 clinical trials for conditions such as Alport syndrome and chronic kidney disease (CKD), demonstrating promising results in improving kidney morphology and function in preclinical studies.

The company’s pipeline includes multiple clinical studies evaluating Vonafexor for various indications, including nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH). The Phase 2a LIVIFY study has shown that Vonafexor can significantly reduce liver fat and improve kidney function parameters in patients with advanced NASH. These findings support the potential of Vonafexor as a best-in-class therapeutic option for patients with diseases that compromise renal function, highlighting its role in addressing unmet medical needs in this area.

France

ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function.

The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH). Roughly 30-50% of NASH patients have CKD through common bidirectional pathways leading to severe renal impairment.

Liver-related infectious diseases such as chronic Hepatitis B and Hepatitis D are also addressed with Vonafexor.

ENYO Pharma

Company Details